Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Inhibition of GCase in patient derived fibroblast cells using 5'pentafluorobenzoylaminofluorescein-di-beta-D-glucoside as substrate assessed as substrate hydrolysis by FACS analysis
Assay data:4 Active, 4 Activity ≤ 1 µM, 4 Tested
SummaryRelated BioAssays by Target
Inhibition of recombinant GCase (unknown origin) using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate at pH 4.5
Assay data:4 Active, 1 Activity ≤ 1 µM, 4 Tested
Chaperone activity at GCase N370S GBA mutant in patient derived fibroblast cell assessed as GCase level incubated for 5 days by immunocytochemistry assay
Assay data:2 Active, 2 Activity ≤ 1 µM, 4 Tested
Chaperone activity at GCase N370S GBA mutant in patient derived fibroblast cell using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate assessed as substrate cleavage by measuring concentration required for maximal response incubated for 5 days by fluorescence based assay
Assay data:38 Active, 30 Activity ≤ 1 µM, 39 Tested
Chaperone activity at GCase N370S GBA mutant in patient derived fibroblast cell using 4-methylumbelliferyl-beta-D-glucopyranoside as substrate assessed as substrate cleavage by measuring maximal response incubated for 5 days by fluorescence based assay relative to isofagomine
Assay data:36 Tested
Enzyme Kinetics - Measuring Inactivation Rates of Inhibitors from US Patent US11826435: "Conduritol aziridine derivatives and uses thereof"
Assay data:5 Active, 3 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Inhibition of human GCase
Assay data:4 Active, 3 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of human GCase assessed as reduction of 4-methylumbelliferone liberation using 4-methylumbelliferyl-beta-glucopyranoside as substrate incubated for 30 mins by fluorescence spectrophotometry
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
Inhibition of human GCase assessed as reduction of 4-methylumbelliferone liberation using 4-methylumbelliferyl-beta-glucopyranoside as substrate preincubated with enzyme for 45 mins followed by substrate addition and measured after 30 mins by fluorescence spectrophotometry
Assay data:6 Active, 1 Activity ≤ 1 µM, 9 Tested
Inhibition of human GCase assessed as reduction of 4-methylumbelliferone liberation using 4-methylumbelliferyl-beta-glucopyranoside as substrate preincubated with enzyme for 10 mins followed by substrate addition by fluorescence spectrophotometry
Assay data:2 Active, 2 Activity ≤ 1 µM, 5 Tested
Inhibition of human recombinant GCase using 4-methylumbelliferyl beta-D-glucopyranoside as substrate incubated for 20 mins by fluorescence-based analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Enzyme Activity Assay (pH=7.0) from US Patent US10501435: "Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity"
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Enzyme Activity Assay (pH=5.9) from US Patent US10501435: "Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity"
Enzyme Activity Assay (pH=5.0) from US Patent US10501435: "Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity"
Enzyme Assay from US Patent US9402837: "Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase"
Assay data:9 Active, 2 Activity ≤ 1 µM, 20 Tested
Enzyme Assay from US Patent US9119845: "Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase"
Assay data:10 Active, 2 Activity ≤ 1 µM, 20 Tested
Enzyme Activity Assay from US Patent US9056847: "Activity based probes (ABPs) interacting with glycosidases"
Assay data:3 Active, 1 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 3 Tested
Enzyme Inhibition Assay from US Patent US8604206: "Compositions for preventing and/or treating degenerative disorders of the central nervous system"
Assay data:7 Active, 1 Activity ≤ 1 nM, 7 Activity ≤ 1 µM, 7 Tested
GCase Ki Assay from Article 10.1002/cbic.201300197: "New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease."
Assay data:12 Active, 12 Activity ≤ 1 µM, 12 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Target
GCase IC50 Assay from Article 10.1002/cbic.201300197: "New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease."
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on